DC HEALTHCARE REPORTED FY2023 Q4 FINANCIAL RESULTS

Group Expected to Fuel Growth with New Branches

KUALA LUMPUR, 27 FEBRUARY 2024 – DC Healthcare Holdings Berhad ("DC Healthcare" or the "Group"), an aesthetic medical services provider specialising in the provision of non-invasive and minimally invasive procedures, today announced the financial results for the fourth quarter ended 31 December 2023 (“4Q FY2023”). The Group reported a revenue of RM17.6 million, predominantly from aesthetic services, which contributed approximately 83.1% to the total quarterly revenue.

The year ended on a positive note with an annual revenue of RM67.8 million, with aesthetic services accounting for 86.3% of the year's total revenue. The Group achieved a Profit Before Tax (“PBT”) of RM5.1 million for the year, after accounting for administrative expenses, including one-off costs related to the IPO exercise. Adjusting for these non-recurring expenses, the adjusted PBT stands at RM8.9 million, showcasing the Group's underlying operational strength.

Quarter-on-quarter, the Group experienced a revenue uplift from RM15.5 million to RM17.6 million, chiefly attributed to the enhanced performance in aesthetic services. The decrease in Loss Before Tax (“LBT”) from RM3.1 million in the previous quarter to RM0.3 million in the current period is indicative of strategic investments in our growth trajectory. This includes increased capital expenditure to expand our branch network, which, while temporarily elevating our operating expenses, is a clear investment in our long-term vision.

Looking ahead, DC Healthcare is committed to continuous growth, with a focus on outlet expansion, including the recently operational branches in Ipoh and Taman Molek, Johor Bahru, expected to contribute positively in the coming quarters. The Group is also proud to announce the appointment of Prof. Datuk Dr. Kj. Rohaizat Bin Hj. Yon, renowned as 'Panglima Covid KKM' or 'MOH COVID-19 War General', as the Group's medical advisor. His vast experience in public health will be invaluable in guiding DC Healthcare's clinical policies and practices.

Dr. Chong Tze Sheng, Managing Director of DC Healthcare, reflected on financial year 2023, "This year has truly been a transformative period for DC Healthcare, underscored by our strategic expansions, the welcoming of esteemed Medical Advisor Datuk Dr. Kj. Rohaizat Bin Hj. Yon, and the successful opening of our new branches in Taman Molek and Ipoh. While we've navigated through short-term hurdles, our trajectory towards growth in 2024 looks incredibly promising.”

He added “As we move forward, our focus remains steadfast on setting new standards in aesthetic medicine, inspired by our dedication to excellence, innovation, and the deep-seated trust placed in us by our clients. With these solid foundations, DC Healthcare is not just aiming for success in the coming year but setting the stage for a legacy of leadership and excellence in the industry."

As the aesthetic medicine market is forecasted to expand at an impressive CAGR of 18.8% through to 2027, DC Healthcare is optimally poised to harness this upward trajectory. The strategic establishment of new branches in Ipoh and Taman Molek, Johor Bahru not only extends our footprint but is set to be a pivotal driver of our future growth. These expansions, aligned with the rising demand in the dynamic healthcare landscape, solidify our position as a front-runner, promising a luminous future for DC Healthcare and its stakeholders.